These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30006566)

  • 21. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
    Kalathil SG; Thanavala Y
    Cells; 2021 May; 10(6):. PubMed ID: 34071188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
    Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-506 Promotes Natural Killer Cell Cytotoxicity against Human Hepatocellular Carcinoma Cells by Targeting STAT3.
    Su Z; Ye X; Shang L
    Yonsei Med J; 2019 Jan; 60(1):22-29. PubMed ID: 30554487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.
    Chew V; Tow C; Huang C; Bard-Chapeau E; Copeland NG; Jenkins NA; Weber A; Lim KH; Toh HC; Heikenwalder M; Ng IO; Nardin A; Abastado JP
    J Natl Cancer Inst; 2012 Dec; 104(23):1796-807. PubMed ID: 23197495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy.
    Xu X; Xing B; Hu M; Xu Z; Xie Y; Dai G; Gu J; Wang Y; Zhang Z
    Cytotherapy; 2010 Apr; 12(2):190-200. PubMed ID: 19929456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles.
    Wu M; Mei F; Liu W; Jiang J
    Biomed Pharmacother; 2020 Jan; 121():109637. PubMed ID: 31810126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma.
    Shin SK; Oh S; Chun SK; Ahn MJ; Lee SM; Kim K; Kang H; Lee J; Shin SP; Lee J; Jung YK
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1717-1727. PubMed ID: 38800890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kbtbd2 inhibits the cytotoxic activity of immortalized NK cells through down-regulating mTOR signaling in a mouse hepatocellular carcinoma model.
    Dai K; Huang Y; Chen Z; Sun X; Yang L; Jiang Y
    Eur J Immunol; 2018 Apr; 48(4):683-695. PubMed ID: 29331106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.
    Han Q; Wang Y; Pang M; Zhang J
    J Exp Clin Cancer Res; 2017 Nov; 36(1):156. PubMed ID: 29115974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
    Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA.
    Wan LL; Zhang DQ; Zhang JN; Ren LQ
    J Zhejiang Univ Sci B; 2017 Jun; 18(6):522-531. PubMed ID: 28585428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.
    Zhuang L; Fulton RJ; Rettman P; Sayan AE; Coad J; Al-Shamkhani A; Khakoo SI
    Hepatol Int; 2019 Jan; 13(1):75-83. PubMed ID: 30467624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scorpion venom activates natural killer cells in hepatocellular carcinoma via the NKG2D-MICA pathway.
    Chen H; Zhidan W; Xia R; Zhaoxia W; Qing J; Qiang G; Haipeng Y; Hengxiao W
    Int Immunopharmacol; 2016 Jun; 35():307-314. PubMed ID: 27089390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Combined Antitumor Effects of
    Zhang J; Wu N; Lian Z; Feng H; Jiang Q; Chen X; Gong J; Qiao Z
    Technol Cancer Res Treat; 2017 Dec; 16(6):1083-1091. PubMed ID: 29332456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.
    Jinushi M; Takehara T; Tatsumi T; Hiramatsu N; Sakamori R; Yamaguchi S; Hayashi N
    J Hepatol; 2005 Dec; 43(6):1013-20. PubMed ID: 16168521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
    Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
    Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.